Pharmacological blockade of soluble epoxide hydrolase attenuates the progression of congestive heart failure combined with chronic kidney disease: insights from studies with fawn-hooded hypertensive rats

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F19%3A00077642" target="_blank" >RIV/00023001:_____/19:00077642 - isvavai.cz</a>

Alternative codes found

RIV/00216208:11130/19:10394225 RIV/00216208:11310/19:10394225 RIV/61989592:15110/19:73599985 RIV/00098892:_____/19:N0000124

Result on the web

<a href="https://www.frontiersin.org/articles/10.3389/fphar.2019.00018/full" target="_blank" >https://www.frontiersin.org/articles/10.3389/fphar.2019.00018/full</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3389/fphar.2019.00018" target="_blank" >10.3389/fphar.2019.00018</a>

Result language

angličtina

Original language name

Pharmacological blockade of soluble epoxide hydrolase attenuates the progression of congestive heart failure combined with chronic kidney disease: insights from studies with fawn-hooded hypertensive rats

Original language description

An association between congestive heart failure (CHF) and chronic kidney disease (CKD) results in extremely poor patient survival rates. Previous studies have shown that increasing kidney epoxyeicosatrienoic acids (EETs) by blocking soluble epoxide hydrolase (sEH), an enzyme responsible for EETs degradation, improves the survival rate in CHF induced by aorto-caval fistula (ACF) and attenuates CKD progression. This prompted us to examine if sEH inhibitor treatment would improve the outcome if both experimental conditions are combined. Fawn-hooded hypertensive (FHH) rats, a genetic model showing early CKD development was employed, and CHF was induced by ACF. Treatment with an sEH inhibitor was initiated 4 weeks after ACF creation, in FHH and in fawn-hooded low-pressure (FHL) rats, a control strain without renal damage. The follow-up period was 20 weeks. We found that ACF FHH rats exhibited substantially lower survival rates (all the animals died by week 14) as compared with the 64% survival rate observed in ACF FHL rats. The former group showed pronounced albuminuria (almost 30-fold higher than in FHL) and reduced intrarenal EET concentrations. The sEH inhibitor treatment improved survival rate and distinctly reduced increases in albuminuria in ACF FHH and in ACF FHL rats, however, all the beneficial actions were more pronounced in the hypertensive strain. These data indicate that pharmacological blockade of sEH could be a novel therapeutic approach for the treatment of CHF, particularly under conditions when it is associated with CKD.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30104 - Pharmacology and pharmacy

Project

<a href="/en/project/NV17-28220A" target="_blank" >NV17-28220A: Pharmacological targeting of cytochrome P-450-derived metabolites of arachidonic as a new approach to treatment of congestive heart failure</a><br>

Continuities

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year

2019

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Frontiers in pharmacology [online]

ISSN

1663-9812

e-ISSN

—

Volume of the periodical

10

Issue of the periodical within the volume

January 23

Country of publishing house

CH - SWITZERLAND

Number of pages

16

Pages from-to

"art. no. 18"

UT code for WoS article

000456509000002

EID of the result in the Scopus database

2-s2.0-85064985153